<DOC>
	<DOCNO>NCT01749904</DOCNO>
	<brief_summary>In participant diagnosis open angle glaucoma ( OAG ) ocular hypertension ( OHT ) , primary objective demonstrate mean IOP reduction 3 month treatment BOL-303259-X daily ( QD ) non-inferior timolol maleate 0.5 % twice daily ( BID ) . The secondary objective demonstrate superiority BOL-303259-X QD timolol maleate 0.5 % BID . This assessment perform non-inferiority BOL-303259-X QD timolol maleate 0.5 % BID determine . An open label safety phase conduct end Visit 6 ( 3 month ) participant receive BOL-303259-X QD additional 9 month .</brief_summary>
	<brief_title>Comparing Safety Efficacy BOL-303259-X With Timolol Maleate Subjects With Open-Angle Glaucoma Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Participants must diagnosis OAG ( include pigmentary pseudoexfoliative ) OHT 1 eye . Participants must meet follow IOP requirement Visit 3 mean/median IOP ≥ 24 mmHg minimum 2 time point eye IOP ≤ 36 mmHg 3 measurement time point eye . Participants bestcorrected visual acuity ( BCVA ) , use Early Treatment Diabetic Retinopathy Study ( ETDRS ) protocol , +0.7 logMAR unit ( Snellen equivalent approximately 20/100 ) good either eye . Participants know hypersensitivity contraindication latanoprost , NO treatment , timolol maleate , betaadrenergic receptor antagonists ingredient study drug . Participants central corneal thickness great 600 μm either eye . Participants advance glaucoma participant cup/disc ratio great 0.8 history split fixation , field loss threaten fixation either eye . Participants intact posterior capsule either eye . Participants aphakia either eye . Participants previous active corneal disease either eye . Participants current history severe dry eye either eye . Participants current history optic disc hemorrhage either eye . Participants current history central/branch retinal vein artery occlusion either eye . Participants current history macular edema either eye . Participants narrow angle ( 3 quadrant less Grade 2 accord Shaffer 's anterior chamber angle grade system ) Participants angle closure , congenital , secondary glaucoma , participant history angle closure either eye . Participants diagnosis clinically significant progressive retinal disease either eye . Participants intraocular infection inflammation either eye within 3 month ( 90 day ) prior Visit 1 ( Screening ) . Participants history ocular laser surgery either eye within 3 month ( 90 day ) prior Visit 1 ( Screening ) . Participants history incisional ocular surgery severe trauma either eye within 3 month ( 90 day ) prior Visit 1 ( Screening ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Intraocular pressure</keyword>
</DOC>